Neumora Therapeutics, Inc.

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in major depressive disorder did not achieve statistical significance on primary or key secondary endpoints, leading to the discontinuation of its development. Following this, the company will reduce its workforce by approximately 35%, expecting annualized cost savings of about $10 million, offset by $2 million in one-time restructuring costs. Neumora projects its cash runway to extend into the third quarter of 2027 and will focus on advancing other pipeline programs, including NMRA-511, NMRA-898, and NMRA-215, with anticipated milestones over the next 12 months.

Neumora Therapeutics reported a reduced net loss of $53.5 million for Q1 2026, an improvement from $68.0 million in Q1 2025. The clinical-stage biopharmaceutical company also saw a significant decrease in total operating expenses by 25.5% to $52.9 million. As of March 31, 2026, cash and cash equivalents stood at $147.1 million, with the company continuing to incur losses and expecting to raise additional capital to fund its operations and pipeline development.

Neumora Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a net loss of $53.5 million. The company maintained a strong financial position with $147.1 million in cash and cash equivalents, projected to support operations into the third quarter of 2027. Neumora also provided key pipeline updates, including the full enrollment of navacaprant KOASTAL-2 and -3 studies with joint topline data expected in Q2 2026, and anticipated clinical data for NMRA-511 and NMRA-898 in the second half of 2026.